Findings suggest that everyone infected with HIV may benefit from additional doses of primary vaccination-ScienceDaily

In this study, approximately 114,000 anonymous individuals who were fully vaccinated with either two mRNA vaccines or one J & J viral vector vaccine between June 30, 2021 and December 31, 2021. I analyzed my health record. HIV researchers have found that HIV patients are 28% more likely to have a positive SARS-CoV-2 test result or COVID-19 diagnosis within 9 months of complete vaccination. did. The risk of breakthrough infection during the study period was 3.8% in the non-HIV group and 4.4% in the HIV group.

Results will be published on June 7th JAMA network open..

“These findings can warn all HIV-infected individuals of the high risk of a breakthrough in COVID-19 and provide official recommendations for COVID-19 vaccination for HIV-infected individuals,” Bloomberg School said. Dr. Kelly Althof, Associate Professor of Research and Senior Author of Research, said. Faculty of Epidemiology.

Public health officials have been concerned that the risk of COVID-19 for people with weakened immunity, including HIV-infected persons, is potentially increased since the beginning of the pandemic. The Center for Disease Control and Prevention is currently in the primary vaccination series for people with “moderate or severe immunodeficiency” (a category that includes untreated or HIV-infected individuals with low CD4 T cell counts (less than 200 cells per microliter)). Vaccine booster as part of, followed by booster immunization. Previous studies have relatively little data on the results of vaccination of HIV-infected persons.

For their study, Althoff and her colleagues pooled individual-level data from four US medical systems to create a research group named the Corona Infectious Virus Epidemiology Team (CIVET) Cohort. The CIVET cohort contains anonymized records from private health insurance companies, veterans’ health systems, and academic health systems. Patients in the study population were treated for various conditions prior to the COVID-19 pandemic. Researchers examined the records of 113,994 people who were fully vaccinated by June 30, 2021. Match 33,029 HIV-positive patients in the sample with 80,965 HIV-negative patients (age, race, gender, and date of full vaccination). They compared the SARS-CoV-2 breakthrough infection rates of the two groups during the first 9 months after vaccination, or until December 31, 2021, whichever comes first.

The breakthrough rate (3.8% in the non-HIV group and 4.4% in the HIV group) is much lower than the COVID-19 rate in unvaccinated people, suggesting a strong protective effect of vaccination. However, the analysis showed that the overall risk of breakthrough infections was 28% higher in the HIV group compared to the non-HIV group after adjusting for differences between the groups.

In addition, this study found an increased risk of breakthroughs associated with increased immunosuppression, as measured by a decrease in CD4 count. People with a CD4 count show moderate immunosuppression in people with HIV-200-350 cells / mm³ Range-The risk of breakthroughs was statistically significantly increased compared to people who were not infected with HIV. This suggests that people with HIV and moderate immunosuppression may need to be included in the CDC’s guidelines for additional doses of vaccines in the primary vaccination series, Altoff says.

“The policy makers who establish the guidelines are not only for severe or untreated HIV patients, but also for moderately immunosuppressed patients, and even for all HIV-infected individuals, with the benefits of additional doses of the primary series of vaccines. Risks need to be considered, “says the study. Lead author Dr. Sally Coburn, a post-doctoral fellow in the Department of Epidemiology at Bloomberg School.

Althoff et al. Follow up studies to determine whether people vaccinated against HIV have high breakthrough infection rates as well as high post-breakthrough hospitalization rates.

“Analysis of groundbreaking COVID-19 infections in HIV-infected persons in the United States” by Sally Coburn, Elizabeth Humes, Raynell Lang, Cameron Stewart, Brenna Hogan, Kelly Gebo, Sonia Napravnik, Jessie Edwards, Lindsay Co-authored. Browne, Lesley Park, Amy Justice, Kirsha Gordon, Michael Horberg, Julia Certa, Eric Watson, Celena Jefferson, Michael Silverberg, Jacek Skarbinski, Wendy Leyden, Carolyn Williams, Keri Althoff

This study was funded under the North American AIDS Cohort Collaboration (NA-ACCORD, U01AI069918) on research and design from the National Institute of Allergic Infectious Diseases, which is part of the National Institute of Health.